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ABSTRACT 
Background 
To better understand a potential association of elevated C-reactive protein (CRP) 
with progression of chronic kidney disease (CKD), we examined the relationship 
of CRP with the development of end-stage renal disease (ESRD) in the Trial to 
Reduce cardiovascular Events with Aranesp Therapy (TREAT). 
 
Study Design 
Post-hoc analysis of a randomized controlled trial. 
 
Setting and Participants 
4,038 patients with type 2 diabetes, CKD and anemia in the TREAT study. 
 
Predictor 
Baseline serum concentrations of CRP. 
 
Outcomes 
The main outcomes are ESRD, doubling of serum creatinine, composite of 
ESRD/doubling of serum creatinine and the composite of death or ESRD. 
 
Measurements 
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We fit unadjusted and adjusted Cox regression models to test the association of 
baseline CRP with time to development of the outcomes of interest 
 
Results 
The mean age of participants was 67 years, 43% were male and 64% were 
white.  Approximately half of the patients (48%) had a CRP concentration of >3 
mg/L; 668 patients developed ESRD, while 1270 developed the composite 
outcome of death or ESRD.  Compared to patients with baseline CRP ≤3 mg/L, 
those with moderate-markedly elevated levels of CRP (≥6.9 mg/L; 24% of 
patients) had a higher adjusted risk of ESRD (HR 1.32; 95%CI 1.07-1.63) and the 
composite outcome of death or ESRD (HR 1.41; 95%CI 1.21-1.64). Although 
non-significant, similar trends were noted in competing risk models. 
 
Limitations 
Results may not be generalizable to non-diabetic CKD or diabetic CKD in the 
absence of anemia. 
 
Conclusions 
Elevated concentrations of baseline CRP are common in type 2 diabetic patients 
with anemia and CKD, and are associated with the future development of ESRD 
and the composite of death or ESRD.   
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Introduction 
Chronic kidney disease (CKD) affects approximately 11.5% of the general 
population1 and 40% of those with self-reported diabetes mellitus in the United 
States.2 Diabetes is a major risk factor for the progression of CKD and is the 
leading cause of end-stage renal disease (ESRD) in the United States, 
accounting for approximately 50,000 new cases in 2012 alone.2   
Elevated concentration of C-reactive protein (CRP), a biomarker 
associated with the presence of inflammation, is known to be associated with the 
development of future cardiovascular (CV) events in patients with3,4 and without a 
prior history of CV disease,5,6 and in patients with CKD.7,8 CKD is widely 
recognized as a risk factor for CV disease, with the majority of patients with 
diabetes and CKD ultimately dying from CV causes.9 In light of these 
relationships, it has been postulated that chronic inflammation may be a common 
etiological factor for the progression of both conditions.  However, to date, 
evidence supporting an association of CRP with kidney function decline (as 
measured by changes in serum creatinine or estimated glomerular filtration rate 
[eGFR]) is conflicting, with some studies reporting the presence of a significant 
association, 10-14 while others have not. 15-17  
The Trial to Reduce cardiovascular Events with Aranesp Therapy 
(TREAT)18 provided an opportunity to perform an examination of the association 
of baseline CRP with the time to the adjudicated outcomes of 1) ESRD and 2) the 
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composite of death or ESRD in patients with type 2 diabetes (T2DM), CKD and 
anemia. We hypothesized that individuals with higher baseline CRP 
concentrations would be at greater risk for development of ESRD, and death or 
ESRD.   
 
Methods 
Study design and population 
The design and original results of TREAT (trial registration: 
www.ClinicalTrials.gov; study number: NCT00093015) have been published. 18,19 
Briefly, TREAT was a prospective, double-blind, randomized controlled trial of 
darbepoetin alfa versus placebo for the treatment of anemia in 4,038 patients 
with T2DM, eGFR of 20-60 mL/min/1.73m2 according to the 4-variable MDRD 
(Modification of Diet in Renal Disease) Study equation, hemoglobin level <11.0 
g/dL, and transferrin saturation >15%.  Notable exclusion criteria included a 
recent (within 12 weeks) CV event, grand mal seizure, major surgery, or prior use 
of an erythropoiesis stimulating agent (ESA), uncontrolled hypertension, known 
human immunodeficiency virus infection, current use of intravenous antibiotics, 
chemotherapy or radiotherapy, malignancy (except basal cell or squamous cell 
carcinoma of the skin), active bleeding, hematologic diseases, pregnancy, or 
kidney transplant recipients.  All patients gave written informed consent for 
participation in the primary trial and the serum samples used in this analysis 
(Partners IRB 2005P000170). 
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Exposures and Outcomes 
 The primary exposure of interest was the baseline serum concentration of 
CRP.  All baseline samples were stored locally by individual sites at -20°C before 
shipment on dry ice for long-term storage at -70°C in a central tissue repository.  
CRP was measured using an immuno-turbidimetric assay.  This was a standard-
sensitivity assay with a lower limit of detection of 3 mg/L.  Therefore for the 
purposes of these analyses, CRP was categorized as normal (≤3 mg/L), mildly 
elevated (>3.0 to <6.9 mg/L) and moderate-markedly elevated (≥6.9 mg/L).  The 
latter two categories were dichotomized at the median for CRP concentrations 
>3mg/L.    
 The primary outcome of interest was the time from randomization to 
development of ESRD, defined as the initiation of renal replacement therapy 
(RRT; sustained for at least 30 days), initiation of RRT with death within 30 days, 
a physician recommendation to initiate RRT with documented patient refusal, or 
receipt of a kidney transplant.  The secondary outcomes were the time to 
development of: 1) doubling of serum creatinine; 2) the composite of ESRD or 
doubling of serum creatinine; 3) the composite outcome of ESRD or death from 
any cause; 4) composite CV outcome of death from any cause, nonfatal 
myocardial infarction (MI), stroke, heart failure or hospitalization for myocardial 
ischemia; and 5) death from any cause.18 The CV components of the composite 
endpoint, ESRD, and death were adjudicated by a clinical end points committee 
	   8	  
blinded to the treatment assignment.  Sensitivity analyses were also performed to 
examine the association of categories of baseline CRP with: 1) the change in 
eGFR from randomization to the development of ESRD or study exit; and 2) the 
difference in last measured eGFR for those individuals that developed ESRD. 
Change in eGFR was calculated as a linear slope in mL/min/1.73m2/year by 
plotting a line of best fit for all available eGFR measurements (3,544 individuals 
had at least two creatinine measurements from which the eGFR slope could be 
calculated; the mean number of measurements per patient was 5.1).  In 
exploratory analyses, the association of baseline CRP with ESRD was 
determined for the sub-group of patients with CRP concentrations > 3mg/L.   
  
Statistical Analyses 
Continuous variables were examined graphically and recorded as means 
(± standard deviations) for normally distributed data, or medians (with 
interquartile ranges) for non-normally distributed data. Categorical variables were 
examined by frequency distribution and recorded as proportions.  Tests for trend 
across categories of CRP were conducted using linear regression, Cuzick's non-
parametric trend test and the Chi-square test for trend for continuous normal, 
continuous non-normal, and categorical data, respectively. 
The relationship between categories of CRP with time to the events of 
interest was examined by proportional hazards regression.  Initially an 
unadjusted model (Model 1) was fit.  Subsequently, a multivariable adjusted 
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model (Model 2) was fit; this model included terms for potential confounding 
variables that were measured at baseline20,21: age, gender, race, estimated GFR, 
log-transformed urine protein/creatinine ratio, history of acute renal failure (ARF), 
duration of T2DM at baseline, HbA1c, retinopathy, insulin use, body mass index, 
hemoglobin, serum albumin, coronary artery disease (angina, myocardial 
infarction, coronary artery bypass graft, percutaneous coronary intervention), 
cerebrovascular disease (including transient ischemic attack and carotid artery 
disease), peripheral arterial disease (including peripheral artery stenosis and 
aortic aneurysm repair), heart failure, systolic blood pressure, low-density 
lipoprotein concentration (LDL), statin therapy, angiotensin converting enzyme 
(ACE) inhibitor or angiotensin receptor blocker (ARB) therapy, smoking status 
(current, former, never), serum ferritin, transferrin saturation, iron therapy and 
randomized treatment assignment. The proportionality assumption was assessed 
on the basis of Schoenfeld residual testing. Additional models were created that 
included the corresponding predictor-time interaction variables in situations 
where violation of the proportional hazards assumption was evident.  Additionally, 
a Cox regression spline model was fit to examine the continuous association of 
baseline CRP with the development of ESRD.  For the purposes of this analysis, 
the 2,112 individuals with baseline CRP ≤3 mg/L were assumed to have a 
CRP=3 mg/L, which was taken as the reference value.  Subsequently, as 
mortality may preclude the development of ESRD or doubling of serum 
creatinine, a multivariable adjusted competing risk model was fit according to the 
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method of Fine and Gray22 in order to estimate the cumulative incidence function 
for ESRD, doubling of serum creatinine, and the composite of ESRD/doubling of 
serum creatinine, where death was considered as the competing risk. 
For the sensitivity analyses, unadjusted and adjusted linear regression 
models were fit to estimate the differences in the slope of eGFR according to 
baseline CRP categories.  For those who went on to develop ESRD, trend tests 
were used to determine the association of the last measured eGFR with 
increasing categories of baseline CRP.  
Nominal 2-sided p values of <0.05 were considered statistically significant. 
All analyses were performed using STATA 13.0MP (College Station, Tex., USA). 
 
Results 
Baseline Characteristics 
 The primary cohort consisted of 4,038 individuals (57% women) with a 
median age of 68 years.18 Just over half of individuals (52.3%) had a baseline 
CRP concentration at or below the lower limit of detection (≤3.0 mg/L).  Of the 
remainder, 953 individuals (23.6%) had a mildly elevated CRP (>3.0 to <6.9 
mg/L) and 973 (24.1%) had a moderate-markedly elevated level (≥6.9 mg/L).   
Individuals in the higher CRP categories were more likely to be younger, female, 
to have a history of ARF, peripheral arterial disease and heart failure, to be a 
current or former smoker, and to have higher LDL and ferritin concentrations. In 
addition, those in the higher CRP categories were also more likely to use insulin, 
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have a higher BMI and higher glycated hemoglobin, but to have lower 
hemoglobin and transferrin saturations, and were less likely to have retinopathy 
or to be taking a statin or an ACEi or ARB. Although serum creatinine 
concentration was statistically significantly higher (and eGFR lower) in the 
patients in the higher CRP categories, the absolute differences were very small 
and unlikely to be of clinical importance.  No significant trend was noted in 
relation to baseline proteinuria (Table 1).   
 
Association of Baseline CRP with Development of End-Stage Renal Disease 
 During median follow-up time of 2.2 years a total of 668 adjudicated ESRD 
events were recorded.  In unadjusted analyses, compared with individuals with 
CRP ≤3.0 mg/L, those in the mildly elevated category had a 21% greater risk of 
developing ESRD (HR 1.21; 95%CI 1.01-1.46; p=0.04), while those in the 
moderate-markedly elevated category had 37% greater risk (HR 1.37; 95%CI 
1.14-1.64; p=0.001 [Figure 1]).  In the fully adjusted analyses (Model 2), 
compared with individuals with CRP ≤3.0 mg/L, those in the moderate-markedly 
elevated category of baseline CRP had 32% greater risk of developing ESRD 
(HR 1.32; 95%CI 1.07-1.63; p=0.01 [Table 2 and Table 3]). Effect estimates were 
essentially unchanged when time-varying coefficients were added to the model to 
address concerns of potential violation of the proportional hazards assumption 
(Supplementary Table A). Using a multivariable competing risk model (with death 
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as the competing outcome) gave similar findings, although the hazard ratio was 
somewhat attenuated (Table 2).  
Similar trends were noted when sub-group analyses of individuals with 
baseline CRP >3mg/L (n=1,926) were performed (Supplementary Table B). 
When CRP was examined as a continuous variable there was evidence for a 
monotonic association of higher CRP with increasing risk of ESRD (Figure 2).  
 
Association of Baseline CRP with Doubling of Serum Creatinine, and the 
composite of ESRD or Doubling of Serum Creatinine 
 During a median follow-up of 2.1 years the endpoint of doubling of serum 
creatinine occurred in 428 individuals.  There was no significant association of 
elevated categories of baseline CRP with the risk of development of doubling of 
serum creatinine, or with the development of the composite outcome of ESRD or 
doubling of serum creatinine (Table 2).  Effect estimates were essentially 
unchanged when time-varying coefficients were added to the model to address 
concerns of potential violation of the proportional hazards assumption 
(Supplementary Table A). Using a multivariable competing risk model (with death 
as the competing outcome) higher baseline CRP was not associated with either 
doubling of serum creatinine or the composite of ESRD/doubling of serum 
creatinine (Table 2).” 
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Association of Baseline CRP with Development of the Composite of Death or 
End-Stage Renal Disease, the CV Composite Outcome and Death from Any 
Cause 
 During a median follow-up period of 2.3 years a total of 1,270 adjudicated 
composite events of death or ESRD were recorded.  In unadjusted models, 
compared with CRP ≤3 mg/L, there was a 21% (HR 1.21; 95%CI 1.05-1.39; 
P=0.01) and 57% (HR 1.57; 95%CI 1.38-1.79; P<0.001) greater risk, 
respectively, of the combined end-point with increasing categories of baseline 
CRP (Tables 2 and 3).  In the fully adjusted model (Model 2), the effects 
estimates were attenuated, but remained significant for the moderate-markedly 
elevated CRP category (HR 1.41; 95%CI 1.21-1.64; p<0.001).  Similar patterns of 
association were noted for the CV composite end point and all-cause death 
(Table 2).   
 
Association of Baseline CRP with Change in eGFR  
 The association of baseline categories of CRP with the change in eGFR 
(mL/min/1.73m2/year) from randomization to development of ESRD or study exit 
was then assessed.  The median change in eGFR in the whole cohort was -1.8 (-
5.9 to 1.4) mL/min/1.73m2/year.  In unadjusted analyses, compared with 
individuals with normal baseline CRP (≤3 mg/L), there was no evidence for a 
significant difference in the change in eGFR in either the mildly elevated 
(difference of -0.3 mL/min/1.73m2/year; 95%CI -1.1 to 0.5; P=0.50) or moderate-
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markedly elevated (difference of 0.4 mL/min/1.73m2/year; 95%CI -0.4 to 1.2; 
P=0.30) CRP categories.  Similar findings were noted in the adjusted models: 
difference of -0.2 mL/min/1.73m2/year (95%CI -1.0 to 0.5; P=0.56) for the mildly 
elevated CRP category and a difference of 0.5 mL/min/1.73m2/year (95%CI -0.3 
to 1.3; P=0.25) for the moderate-markedly elevated category, compared with 
individuals with a normal baseline CRP (≤3 mg/L; Supplementary Table C).   
For those that ultimately went on to develop ESRD, the median [25th to 
75th percentile] last measured eGFR was lower in patients with lower CRP 
measurements: 14.9 [11.6 to 20.9] mL/min/1.73m2 for those with CRP ≤3 mg/L; 
16.8 [12.7 to 23.3] mL/min/1.73m2  for those with CRP >3 to <6.9 mg/L; and 17.1 
[12.6 to 22.6] mL/min/1.73m2  for those with CRP ≥6.9 mg/L; P for trend=0.02).  
The median time that these measurements were collected prior to the declaration 
of ESRD was 88 days for those with CRP ≤3 mg/L,106 days for those with CRP 
>3 to <6.9 mg/L and 96 days for those with CRP ≥6.9 mg/L (P for trend=0.89).   
 
Discussion 
 In this post-hoc analysis of the TREAT study we found that higher baseline 
concentrations of CRP were associated with greater risk of the adjudicated 
outcomes of ESRD and the composite of death or ESRD, but not with changes in 
eGFR or doubling of serum creatinine.  
CRP (MW ~23 kDa) is a member of the pentraxin protein family, which is 
intimately involved in the activity of the innate immune system.23 CRP is primarily 
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produced by hepatocytes and its synthesis can be markedly up-regulated as part 
of the acute phase response.24 Although cause and effect has not been proven, 
prior epidemiological studies have demonstrated a clear association of higher 
CRP concentrations with the future development of myocardial infarction and 
ischemic stroke. 5,6,25 The association of higher levels of CRP with greater risk of 
CV disease also appears to be consistent in patients with a history of CKD. 7,8    
The presence of inflammation has been proposed as a common etiological 
pathway in the pathogenesis and progression of both CV and CKD.  However, to 
date, the prior evidence linking CRP with progressive decline in renal function is 
conflicting, with some studies reporting no association, 7,15-17 while others have 
reported a positive association. 11,14 Importantly, the ascertainment of the renal 
outcome appears to play an important role in the heterogeneity of prior reports.  
For example, Fried et al. reported a significant association of baseline CRP with 
greater decline in eGFR (using the four-variable MDRD Study equation) in 4,620 
community-based individuals aged <65 years in the CV Health Study (25% had 
diabetes).10 However, an analysis of the same study by Keller et al. failed to find 
such an association when decline in eGFR was assessed using cystatin C.12 In 
another report, Hiramoto et al. found discrepant results in their analyses of 4,966 
participants of the Multi-Ethnic Study of Atherosclerosis (MESA) study: baseline 
CRP was significantly associated with decline in eGFR using cystatin C, but not 
when using serum creatinine (using the CKD-EPI equation).13 Indeed, some have 
questioned the accuracy of estimating equations for GFR in patients with 
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T2DM,26 raising further concerns in relation to the use of changes in such 
parameters over time.   
Our analyses were performed in individuals with the triad of T2DM, 
anemia and CKD.  We did not find a significant association of baseline CRP with 
changes in eGFR (calculated using serum creatinine) or doubling of serum 
creatinine during the study period, but did report an association with development 
of the clinically important adjudicated end-point of ESRD. While we recognize 
that the use of a linear slope to describe progression of CKD in a group of 
patients does not accurately reflect individual rates and patterns of progressive 
renal function decline, it is also noteworthy that the last available eGFR prior to 
the development of ESRD was higher across increasing CRP categories.   
As higher baseline CRP was not associated with progression of CKD as 
measured by a decline in eGFR (but was associated with progression to clinical 
ESRD), a tentative hypothesis might be that higher CRP identifies individuals with 
a greater burden of comorbidities who may be more likely to require earlier 
initiation of renal replacement therapy.  Alternatively, higher CRP may identify 
individuals with a greater burden of comorbid conditions leading to 
overestimation of measured GFR due to lower creatinine generation.27 Our 
finding that the risk of developing the CV composite outcome during the trial was 
higher in those with higher baseline CRP provides supportive evidence for both 
possibilities.  
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It is worth noting that moderate-markedly elevated CRP is associated with 
significantly greater risk of death and with a greater risk of ESRD. In the 
competing risk model, the association of elevated CRP with ESRD becomes 
attenuated and of borderline significance.  However, in this model death 
precludes progression to ESRD, and so we may interpret this constellation of 
findings to indicate that, among those who have not died, higher CRP is a risk 
factor for ESRD. This interpretation is supported by the finding that higher CRP is 
associated with a greater risk of developing the composite endpoint of death or 
ESRD. 
The major strengths of our study are the large number of independently 
adjudicated clinical endpoints and detailed data collection that occurred in the 
setting of a double blind randomized controlled trial.  However, there are 
limitations.  The first relates to the use of standard sensitivity measurements of 
CRP with a lower limit of measurement of 3 mg/L, thereby restricting our ability to 
examine CRP as a continuous variable. On the other hand, despite the lack of 
high-sensitivity measurements, 48% of these patients with T2DM, CKD and 
anemia had baseline CRP measurements >3mg/L, which highlights the 
prevalence of underlying inflammation in this important patient population. 
Another limitation is that only one baseline measurement of CRP was available.  
However, the stability of CRP in individual patients has been demonstrated 
previously (albeit in non-CKD patients),28 while the clinical relevance of our 
findings remains applicable, such that those with moderate-markedly elevated 
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CRP measurements (≥6.9 mg/L) were significantly more likely to develop ESRD.  
That the direction of association was similar in the analyses of the composite 
outcome of ESRD or death, the CV composite outcome and the outcome of 
death from any cause, provides additional reassurance of the clinical relevance 
of our findings. In the setting of a secondary analysis of a randomized trial, 
several potential confounding variables had to be considered in the model 
building process.  In this regard it is possible that residual confounding based on 
variables not considered, or due to incomplete adjustment of those that were 
considered, remains present. This post-hoc study was not powered to assess the 
influence of anti-inflammatory therapies or other factors that could potentially 
modify the relationship between CRP and ESRD. Finally, the sample in this study 
consisted of patients with T2DM, CKD and anemia in the setting of a randomized 
controlled trial, limiting the generalizability to individuals without this comorbid 
disease pattern.   
 In conclusion, we found that higher baseline CRP was associated 
with a greater risk of developing ESRD and the composite of death/ESRD in 
patients with the triad of T2DM, CKD and anemia.  When reviewing a patient with 
these comorbidities, the presence of an elevated CRP may prompt the clinician 
to explore for potentially modifiable sources of inflammation, such as infection. 
Whether interventions that lower CRP will result in a reduced risk of ESRD is 
unknown, but may provide opportunities for future research.   
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Table 1.  Baseline Characteristics of the Cohort According to Categories of C-
Reactive Protein 
 
 Baseline CRP  
 Normal 
(≤3 mg/L) 
Mildly Elevated  
(>3.0 to <6.9 
mg/L) 
Moderate-
markedly 
Elevated 
(≥6.9 mg/L) 
Pa 
n 2,112 953 973  
CRP NA 4.5 (3.7-5.4) 13.3 (9.0-23.5)  
Age (years) 67.8 ±10.7 67.1 ±10.6 66.5 ±10.6 0.001 
Male (%) 44.6 40.9 40.5 0.02 
Race (%)    0.17 
     Black 18.6 20.4 23.5  
     Hispanic 16.3 11.0 9.1  
     Other 4.0 2.1 1.0  
     White 61.1 66.5 66.3  
     
Creatinine 
(mg/dL) 
1.8 (1.5-2.3) 1.9 (1.5-2.4) 1.9 (1.5-2.4) 0.04 
eGFR 
(mL/min/1.73m2) 
32 (25-40) 31 (24-39) 31 (24-41) 0.05 
Urine Pr/Cr ratio 0.4 (0.1-1.8) 0.5 (0.2-1.9) 0.4 (0.1-1.9) 0.11 
History of ARF 
(%) 
7.7 10.9 13.2 <0.001 
     
Duration of 
T2DM (years) 
15.5 (8.5-21.6) 15.6 (8.6-21.9) 15.0 (7.5-21.8) 0.24 
HbA1c (%) 6.9 (6.2-7.8) 7.1 (6.3-8.2) 7.1 (6.3-8.1) <0.001 
Neuropathy (%) 47.3 47.0 49.8 0.23 
Retinopathy (%) 50.5 46.1 40.1 <0.001 
Insulin use (%) 44.4 55.1 54.2 <0.001 
BMI (kg/m2) 29.1 (25.7-33.5) 31.2 (26.9-36.1) 32.1 (27.4-
38.5) 
<0.001 
     
Hemoglobin 
(g/dL) 
10.4 ±1.0 10.4 ±1.0 10.3 ±1.0 0.01 
Albumin (g/dL) 4.0 ±0.4 4.0 ±0.4 3.9 ±0.4 <0.001 
     
CAD (%) 35.1 38.7 37.3 0.15 
CVD (%) 17.4 16.5 19.2 0.30 
PAD (%) 18.1 20.4 23.3 <0.001 
HF (%) 29.7 36.7 38.0 <0.001 
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SBP (mmHg) 136.0 ±18.7 137.0 ±18.6 134.6 ±18.9 0.13 
LDL (mg/dL) 89 ±39 94 ±42 93 ±40 0.01 
Statin (%) 61.7 57.0 53.2 <0.001 
ACEi or ARB 
(%) 
82.1% 77.4% 77.2% <0.001 
Smoking    0.01 
     Current (%) 4.5 4.7 6.5  
     Former (%) 38.0 38.7 40.7  
     Never (%) 57.5 56.6 52.8  
Ferritin (mcg/L) 120 (60-240) 133 (66-256) 161 (90-299) <0.001 
Transferrin 
Saturation (%) 
25.6±9.4 24.1±9.6 21.2±8.4 <0.001 
Iron therapy (%) 42.9 42.0 48.8 0.01 
Treatment 
(Darbepoetin 
vs. Placebo, %) 
50.0 50.6 48.7 0.58 
Values for continuous variables are given as mean ±standard deviation or 
median (25th – 75th percentile).   
 
Abbreviations: CRP, C-reactive protein; eGFR, estimated glomerular filtration 
rate; Pr/Cr, protein to creatinine ratio; ARF, acute renal failure; T2DM, type 2 
diabetes mellitus; HbA1c, glycated hemoglobin; BMI, body mass index; CAD, 
coronary artery disease; CVD, cerebrovascular disease; PAD, peripheral arterial 
disease; HF, heart failure; SBP, systolic blood pressure; LDL, low-density 
lipoprotein; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin 
receptor blocker. 
 
a P values refer to a test for trend across increasing category of CRP 
concentration. 
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Table 2. Association of Category of Baseline C-Reactive Protein with Time to 
ESRD, Doubling of Serum Creatinine, Composite of ESRD of Doubling of Serum 
Creatinine, Composite of ESRD or Death, CV Composite, and Death alone 
 
 Hazard Ratio (95% CI) for ESRD 
  
P for 
trend 
Events/Total CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(668/4,038) 
Ref 1.21 (1.01 - 1.46) 1.37 (1.14 – 1.64) P=0.001 
Adjusted 
(598/3,642) 
Ref 1.08 (0.88 – 1.33) 1.32 (1.07 – 1.63) P=0.01 
Competing 
Risk 
(598/3,642) 
Ref 1.01 (0.81-1.25) 1.23 (0.99-1.53) P=0.09 
     
 Hazard Ratio (95% CI) for Doubling of Serum 
Creatinine 
 
Events/Total CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(428/3,654) 
Ref 0.96 (0.76 - 1.22) 1.06 (0.84 – 1.35) P=0.72 
Adjusted 
(367/3,305) 
Ref 0.90 (0.69 – 1.18) 0.94 (0.71 – 1.25) P=0.59 
Competing 
Risk 
(367/3,305) 
Ref 0.86 (0.65-1.14) 0.93 (0.69-1.25) P=0.51 
     
 Hazard Ratio (95% CI) for Composite of 
ESRD/Doubling of Serum Creatinine 
 
Events/Total CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(871/4,038) 
Ref 1.16 (0.99 - 1.37) 1.28 (1.09 – 1.51) P=0.002 
Adjusted 
(769/3,642) 
Ref 1.05 (0.87 – 1.26) 1.17 (0.97 – 1.42) P=0.11 
Competing 
Risk 
(769/3,642) 
Ref 0.99 (0.82-1.20) 1.12 (0.92-1.36) P=0.32 
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 Hazard Ratio (95% CI) for Death or ESRD  
 CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(n=1,270/ 
4,038) 
Ref 1.21 
(1.05 - 1.39) 
1.57 
(1.38 – 1.79) 
P<0.001 
Adjusted 
(n=1,139/ 
3,642) 
Ref 1.11 
(0.96 – 1.29) 
1.41 
(1.21 – 1.64) 
P<0.001 
     
 Hazard Ratio (95% CI) for CV Composite Outcome*  
 CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(n=1,234/ 
4,038) 
Ref 1.26 
(1.09 - 1.45) 
1.77 
(1.55 – 2.02) 
P<0.001 
Adjusted 
(n=1,111/ 
3,642) 
Ref 1.16 
(0.99 – 1.35) 
1.55 
(1.34 – 1.81) 
P<0.001 
     
 Hazard Ratio (95% CI) for Death From Any Cause  
 CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(n=807/ 
4,038) 
Ref 1.20  
(1.00 – 1.43) 
1.85 
(1.57 – 2.16) 
P<0.001 
Adjusted 
(n=734/ 
3,642) 
Ref 1.15  
(0.95 – 1.39) 
1.59  
(1.32 – 1.91) 
P<0.001 
 
The multivariable models were adjusted for age, gender, race, estimated GFR, 
log-transformed urine protein/creatinine ratio, history of acute renal failure, 
duration of T2DM, HbA1c, retinopathy, insulin use, body mass index, 
hemoglobin, serum albumin, coronary artery disease, cerebrovascular disease, 
peripheral arterial disease, heart failure, systolic blood pressure, low-density 
lipoprotein concentration, statin therapy, ACE inhibitor or ARB therapy, smoking 
status, ferritin, transferrin saturation, iron therapy and randomized treatment 
assignment.  Multivariable adjusted competing risk models were fit, with death as 
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the competing outcome, for the endpoints of ESRD, doubling of serum creatinine 
and the composite of ESRD/doubling of serum creatinine.   
 
*CV composite included death from any cause, nonfatal MI, stroke, heart failure 
or hospitalization for myocardial ischemia 
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Table 3. Unadjusted and Multivariable adjusted associations of Baseline Factors 
with Development of End-Stage Renal Disease. 
 Unadjusted   Adjusted 
 Hazard Ratio 
(95% CI) 
P  Hazard Ratio 
(95% CI) 
P 
CRP (mg/L)      
     ≤3.0  Ref -  Ref - 
     >3.0 to <6.9 1.21 
(1.01-1.46) 
0.04  1.08 
(0.88-1.33) 
0.45 
     ≥6.9 1.37 (1.14-
1.64) 
0.001  1.32 
(1.07-1.63) 
0.01 
Age (/10 years) 0.71 
(0.67-0.77) 
<0.001  0.91 
(0.83-1.00) 
0.04 
Male (vs. female) 1.75  
(1.51-2.04) 
<0.001  1.84 
(1.53-2.20) 
<0.001 
Race       
     White Ref -  Ref - 
     Black 1.65 (1.38-
1.97) 
<0.001  1.44 
(1.18-1.77) 
<0.001 
     Hispanic 1.53 (1.23-
1.90) 
<0.001  0.87 
(0.67-1.13) 
0.29 
     Other 1.13 (0.71-
1.82) 
0.71  0.93 
(0.57-1.53) 
0.77 
eGFR 
(/10mL/min/1.73m2 
increase) 
0.40  
(0.36-0.44) 
<0.001  0.46 
(0.41-0.50) 
<0.001 
Log Urine Pr/Cr 
ratio (/unit) 
2.04 
(1.93-2.15) 
<0.001  1.77 
(1.63-1.92) 
<0.001 
History of ARF (vs. 
none) 
1.63  
(1.30-2.03) 
<0.001 
 
 1.42 
(1.12-1.81) 
0.004 
Duration of T2DM 
(/12 months) 
1.01 
(1.01-1.02) 
0.001   1.01 
(1.00-1.02) 
0.03 
HbA1c (/%) 1.10  
(1.05-1.15) 
<0.001  0.98 
(0.93-1.04) 
0.50 
Retinopathy (vs.  
none) 
1.83  
(1.56-2.13) 
<0.001  1.05 
(0.87-1.26) 
0.61 
Insulin use (vs 
none) 
1.55  
(1.33-1.81) 
<0.001  1.11 
(0.92-1.33) 
0.27 
BMI (/10kg/m2) 0.85 
(0.77-0.95) 
0.01  0.84 
(0.73-0.95) 
0.01 
Hemoglobin (/g/dL) 0.78 
(0.73-0.84) 
<0.001  0.95 
(0.88-1.03) 
0.25 
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Albumin (/g/dL) 0.24  
(0.21-0.27) 
<0.001  0.58 
(0.47-0.72) 
<0.001 
CAD (vs. none) 0.94 
(0.80-1.10) 
0.42  1.10 
(0.91-1.32) 
0.34 
CVD (vs. none) 0.94 (0.77-
1.16) 
0.59  1.13 
(0.90-1.42) 
0.28 
PAD (vs. none) 1.09 
(0.90-1.32) 
0.38  1.00 
(0.81-1.25) 
0.98 
HF (vs. none) 1.33  
(1.13-1.55) 
<0.001  1.46 
(1.22-1.75) 
<0.001 
SBP (/10 mmHg) 1.16 
(1.12-1.21) 
<0.001  1.01 
(0.96-1.05) 
0.73 
Statin (vs. none) 0.85 
(0.73-1.00) 
0.04  0.94 
(0.79-1.12) 
0.46 
ACEi/ARB (vs. none) 0.86  
(0.71-1.03) 
0.10  0.97  
(0.79-1.19) 
0.80 
LDL (/10mg/dL) 1.06  
(1.04-1.08) 
<0.001  1.01 
(0.99-1.02) 
0.61 
Smoking      
     Current  Ref -  Ref - 
     Former  0.64 
(0.48-0.86) 
0.004  0.84 
(0.60-1.18) 
0.31 
     Never  0.56 
(0.41-0.75) 
<0.001  0.83 
(0.59-1.15) 
0.26 
Ferritin (/100mcg/L) 1.04  
(1.03-1.06) 
<0.001  1.01  
(0.99-1.03) 
0.27 
Iron Saturation (/%) 1.02  
(1.01-1.02) 
<0.001  1.00  
(1.00-1.01) 
0.33 
Iron therapy (vs. 
none) 
1.08  
(0.93-1.26) 
0.33  1.07  
(0.91-1.26) 
0.42 
Darbepoetin (vs. 
placebo) 
1.01 
(0.87-1.18) 
0.90  1.08 
(0.92-1.27) 
0.36 
The multivariable models were adjusted for age, gender, race, estimated GFR, 
log-transformed urine protein/creatinine ratio, history of acute renal failure, 
duration of T2DM, HbA1c, retinopathy, insulin use, body mass index, 
hemoglobin, serum albumin, coronary artery disease, cerebrovascular disease, 
peripheral arterial disease, heart failure, systolic blood pressure, low-density 
lipoprotein concentration, statin therapy, ACE inhibitor or ARB therapy, smoking 
status, ferritin, transferrin saturation, iron therapy and randomized treatment 
assignment. 
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Figure 1. Kaplan-Meier failure probabilities of the association of baseline 
categories of CRP with risk of ESRD.  
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Figure 2. Spline analysis of the association of CRP with ESRD.  Hazard 
ratios (HR; continuous line) and 95% Upper and Lower Confidence Intervals (UCI 
and LCI; dashed lines) for the association of CRP as a continuous variable with 
the risk of ESRD.  For the purposes of this analysis, the 2,112 individuals with 
baseline CRP ≤3 mg/L were assumed to have a CRP=3 mg/L, which was taken 
as the reference value (large bar at the extreme left of the x-axis).  Effect 
estimates were adjusted for age, gender, race, estimated GFR, log-transformed 
urine protein/creatinine ratio, history of acute renal failure, duration of T2DM, 
HbA1c, retinopathy, insulin use, body mass index, hemoglobin, serum albumin, 
coronary artery disease, cerebrovascular disease, peripheral arterial disease, 
heart failure, systolic blood pressure, low-density lipoprotein concentration, statin 
therapy, ACE inhibitor or ARB therapy, smoking status, ferritin, transferrin 
saturation, iron therapy and randomized treatment assignment.  Estimates are 
presented for CRP values between up to the 95th percentile of recorded values.    
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Supplementary Table A. Association of Category of Baseline C-Reactive 
Protein with Time to ESRD, Doubling of Serum Creatinine, Composite of ESRD 
of Doubling of Serum Creatinine, Composite of ESRD or Death, CV Composite, 
and Death alone 
 Hazard Ratio (95% CI) for ESRD 
  
P for 
trend 
Model 
(Events/Total) 
CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(668/4,038) 
Ref 1.21 (1.01 - 1.46) 1.37 (1.14 – 1.64) P=0.001 
Adjusted 
(598/3,642) 
Ref 1.08 (0.88 – 1.33) 1.32 (1.07 – 1.63) P=0.01 
Adjusted 
non-PHa 
(598/3,642) 
Ref 1.09 (0.89-1.34) 1.31 (1.06-1.63) P=0.01 
     
 Hazard Ratio (95% CI) for Doubling of Serum 
Creatinine 
 
Model 
(Events/Total) 
CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(428/3,654) 
Ref 0.96 (0.76 - 1.22) 1.06 (0.84 – 1.35) P=0.72 
Adjusted 
(367/3,305) 
Ref 0.90 (0.69 – 1.18) 0.94 (0.71 – 1.25) P=0.84 
Adjusted 
non-PHb 
(367/3,305) 
Ref 0.91 (0.69-1.19) 0.95 (0.71-1.26) P=0.62 
     
 Hazard Ratio (95% CI) for ESRD/Doubling of Serum 
Creatinine 
 
Model 
(Events/Total) 
CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(871/4,038) 
Ref 1.16 (0.99 - 1.37) 1.28 (1.09 – 1.51) P=0.002 
Adjusted 
(769/3,642) 
Ref 1.05 (0.87 – 1.26) 1.17 (0.97 – 1.42) P=0.11 
Adjusted 
non-PHc 
(769/3,642) 
Ref 1.04 (0.87-1.25) 1.18 (0.97-1.42) P=0.10 
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 Hazard Ratio (95% CI) for Death or ESRD  
Model 
(Events/Total) 
CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(1,270/ 
4,038) 
Ref 1.21 
(1.05 - 1.39) 
1.57 
(1.38 – 1.79) 
P<0.001 
Adjusted 
(1,139/ 
3,642) 
Ref 1.11 
(0.96 – 1.29) 
1.41 
(1.21 – 1.64) 
P<0.001 
Adjusted 
non-PHd 
(1,139/ 
3,642) 
Ref 1.12 (0.96-1.30) 1.40 (1.20-1.63) P<0.001 
     
 Hazard Ratio (95% CI) for CV Composite Outcome*  
Model 
(Events/Total) 
CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(1,234/ 
4,038) 
Ref 1.26 
(1.09 - 1.45) 
1.77 
(1.55 – 2.02) 
P<0.001 
Adjusted 
(1,111/ 
3,642) 
Ref 1.16 
(0.99 – 1.35) 
1.55 
(1.34 – 1.81) 
P<0.001 
Adjusted 
non-PHe 
(1,111/ 
3,642) 
Ref 1.16 (0.99-1.35) 1.54 (1.33-1.80) P<0.001 
     
 Hazard Ratio (95% CI) for Death From Any Cause  
Model 
(Events/Total) 
CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(807/ 
4,038) 
Ref 1.20  
(1.00 – 1.43) 
1.85 
(1.57 – 2.16) 
P<0.001 
Adjusted 
(734/ 
3,642) 
Ref 1.15  
(0.95 – 1.39) 
1.59  
(1.32 – 1.91) 
P<0.001 
Adjusted 
non-PHf 
Ref 1.15 (0.95-1.39) 1.58 (1.32-1.90) P<0.001 
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(734/ 
3,642) 	  
The multivariable models were adjusted for age, gender, race, estimated GFR, 
log-transformed urine protein/creatinine ratio, history of acute renal failure, 
duration of T2DM, HbA1c, retinopathy, insulin use, body mass index, 
hemoglobin, serum albumin, coronary artery disease, cerebrovascular disease, 
peripheral arterial disease, heart failure, systolic blood pressure, low-density 
lipoprotein concentration, statin therapy, ACE inhibitor or ARB therapy, smoking 
status, ferritin, transferrin saturation, iron therapy and randomized treatment 
assignment. 
*CV composite included death from any cause, nonfatal MI, stroke, heart failure 
or hospitalization for myocardial ischemia 
 
In the case of violations of the proportional hazards assumption, time varying co-
efficients were included in the corresponding multivariable models as follows: a 
race, duration of T2DM, HbA1c, retinopathy, body mass index, estimated GFR, 
log-transformed urine protein/creatinine ratio, albumin, peripheral arterial disease 
and low-density lipoprotein; b HbA1c and estimated GFR; c HbA1c, insulin use, 
body mass index, albumin and low density lipoprotein; d race, log-transformed 
urine protein/creatinine ratio, albumin, peripheral arterial disease and low-density 
lipoprotein; e age, race, treatment assignment, log-transformed urine 
protein/creatinine ratio, albumin and ACEi/ARB use; f log-transformed urine 
protein/creatinine ratio and albumin. 
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Supplementary Table B. Association of Tertiles of Baseline C-Reactive Protein 
with Time to ESRD in Patients with Baseline CRP Above the Lower Limit of 
Detection (>3 mg/L) 
 
 Hazard Ratio (95% CI) for ESRD 
  
P for 
trend 
Model 
(Events/Total) 
Lowest 
Tertile 
Middle Tertile Highest Tertile  
Adjusted 
(308/1,710) 
Ref 0.99 (0.73 - 1.33) 1.32 (0.98 – 1.77) P=0.07 
 
For the purposes of this exploratory analysis only patients with baseline CRP 
concentrations above the lower limit of detection were included (>3 mg/L).  The 
multivariable model was adjusted for age, gender, race, estimated GFR, log-
transformed urine protein/creatinine ratio, history of acute renal failure, duration 
of T2DM, HbA1c, retinopathy, insulin use, body mass index, hemoglobin, serum 
albumin, coronary artery disease, cerebrovascular disease, peripheral arterial 
disease, heart failure, systolic blood pressure, low-density lipoprotein 
concentration, statin therapy, ACE inhibitor or ARB therapy, smoking status, 
ferritin, transferrin saturation, iron therapy and randomized treatment assignment. 
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Supplementary Table C. Difference in eGFR slope according to category of 
baseline C-Reactive Protein 
 
 Difference in eGFR (95% CI) in mL/min/1.73m2/year 
  
P for 
trend 
 CRP ≤3.0 
mg/L 
CRP >3.0 to <6.9 
mg/L 
CRP ≥6.9 mg/L  
Unadjusted 
(n=3,544) 
Ref -0.3 (-1.1 to 0.5) 0.4 (-0.4 to 1.2) P=0.42 
Adjusted 
(n=3,228) 
Ref -0.2 (-1.0 to 0.5) 0.5 (-0.3 to 1.3) P=0.36 	  
The multivariable models were adjusted for age, gender, race, baseline 
estimated GFR, log-transformed urine protein/creatinine ratio, history of acute 
renal failure, duration of T2DM, HbA1c, retinopathy, insulin use, body mass 
index, hemoglobin, serum albumin, coronary artery disease, cerebrovascular 
disease, peripheral arterial disease, heart failure, systolic blood pressure, low-
density lipoprotein concentration, statin therapy, ACE inhibitor or ARB therapy, 
smoking status, ferritin, transferrin saturation, iron therapy and randomized 
treatment assignment. 	  	  
 
